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Background: Persistent infection with high-risk human papillomavirus (HPV) is a major risk factor for malignant
lesions and cervical cancer. A widely studied element in the search for genetic factors influencing risk HPV infection
diseases is allelic variation of the human leukocyte antigen (HLA) locus. The study was designed to search for HLA
susceptibility alleles contributing to the persistence of HPV infection in Mexican women.
Methods: A total of 172 subjects were divided into three groups: 1) HPV–persistent patients; 2) HPV–cleared; and 3)
HPV–reinfected patients. They were screened for HPV types using a polymerase chain reaction (PCR).
PCR-sequence specific oligonucleotide probes (PCR-SSOP) was used for HLA DRB1 and DQB1 typing.
Results: We observed that HLA-DQB1*0501 allele might be associated with susceptibility of reinfection with HPV
(p = 0.01, OR = 4.9, CI 95% = 1.3 -18.7). Allele frequency of HLA-DRB1*14 was particularly reduced in patients with
cancer when compared with the HPV–persistent group (p = 0.04), suggesting that this allele is a possible protective
factor for the development of cervical cancer (OR = 2.98). HLA-DRB1*07 might be associated with viral clearance
(p = 0.04).
Conclusions: Genetic markers for HPV infection susceptibility are different in each population, in Mexicans several
HLA-DQB1 alleles might be associated with an enhanced risk for viral persistence. In contrast, DRB1*14, seems to
confer protection against cervical cancer.
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Infection by human papillomavirus (HPV) is a common
sexually transmitted infectious disease and most sexually
active women have been infected during their lifetime [1].
Persistent infection by oncogenic HPV is a risk factor for
developing cervical cancer (CC), but only a small number
of infected women develop precancerous lesions, and even
fewer develop invasive cancer. This indicates that other
risk factors, such as genetic predisposition, are also very
important. The most important protective immune* Correspondence: habarrera@gmail.com
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distribution, and reproduction in any mediummechanism for CC is the suppression or elimination of
HPV infection by the cell mediated immune response
(CMR) within 1–2 year of exposure [2]. A number of
genetic risk factors have been identified, but their effects
are generally weak. The most prominent among the
known risk factors is the human leukocyte antigen (HLA)
complex, which plays a critical role in susceptibility to CC
[3]. Since the first reported association of HLA-DQ3 with
CC [4], a large number of studies of HLA association with
CC have been published with variable results depending
on the ethnic group.
Affected sib-pair analyses in Swedish women, revealed
an excess sharing of DPB1, DQB1 and DRB1 alleles,
with the strongest evidence for DQB1 and DRB1 [5]. An
analysis of the entire HLA region using microsatellites,tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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risk of developing CC [6]. An increased risk of CC was
also observed in homozygote carriers of the MICA
allele 184, suggesting a recessive effect of this locus [6].
DRB1*04:07-DQB1*03:02 and DRB1*15:01-DQB1*06:02
were clearly associated with susceptibility to HPV-16
positive invasive CC [7], high squamous intraepithelial
lesion (HSIL), and carcinoma in situ, but only in HPV-
16 infected patients [7]. DRB1*15–DQB1*06:02 haplo-
type was also found increased in CC and CC-HPV-16
positive Brazilian patients [8]. Part of the herein
authors published an association of, HLA-DQA1*03:01
in Honduran women [9], which is in linkage disequi-
librium with all HLA-DR4 subtypes in Mestizos, as an
increased risk of developing HSIL and CC. The DQB1*03
group, or some of DQ3 alleles, have been linked with CC
susceptibility in different European, Asian, and African-
American populations [7,10-13]. Some DR-DQ haplotypes
containing DQB1*03:01 allele have been positively asso-
ciated with CC susceptibility: DRB1*11:01-DQB1*03:01 in
Senegalese [14] and US white Europeans [15] and
DRB1*04:01-DQB1*03:01 in US white Europeans [15] and
British females [16]. DRB1*11:02-DQB1*03:01 was also
increased in Hispanics with carcinoma in situ or HSIL [7].
In contrast, there are studies in Canadian and Senegalese
women in which it was not possible to confirm an asso-
ciation between the DQB1*03 allele and the risk of CC or
high grade cervical intraepithelial neoplasia [14,17] and
some studies find a protective role of this allele against
HPV infections and CC [18-20].
Protection has been mainly linked with the HLA-
DRB1*13 group: DRB1*13:01 in patients from Costa Rica
[21], and DRB1*13:01-DQB1*06:03-DQA1*01:03 in Swedish
[22], French and Dutch women with CC [23]. A protective
effect against CC progression was also claimed to be
correlated with DQB1*05, DQA1*01:01/04, DRB1*01:01
and DRB1*13:02 in Brazilians [8]. In Caucasians,
HLA-DRB1*13 and HPV-16/18-negative status, were
independently associated with an increased probability
of regression of low squamous intraepithelial lesion
(LSIL), also suggesting a protective effect against CC
progression [24].
Several HLA and CC association studies have been
published in Mexican women. A significant increase of
HLA-A2 and HLA-DR5 and a significant decrease of
HLA-DR6, HLA-DR2 and HLA-DR1 were shown in
women with CC, using serological techniques [25]. The
DRB1*15-DQB1*06:02 haplotype was associated with
CC in HPV-16 positive females and several DR4-
DQB1*03:02 and DQB1*03:01 haplotypes were nega-
tively associated with CC. However, all alleles except for
those belonging to the DQB1 locus were performed at
the antigen level [26]. Finally, a recent report looking
for the correlation of HPV-16 and CC in Mexicanwomen, showed that DRB1*04:03 influences the risk
of developing HSIL, independently of HPV16 and
DRB1*01:01, it may confer protection against the
development of CC. The HLA-DRB1*04:07 allele was
increased in HPV16 positive patients, confirming that
the HLA association is HPV dependent [27].
The aim of the present study was to investigate if
HLA class II alleles are associated with persistence of
infection, independently of its progression to CC. We
observed that HLA-DQB1*0501 allele might be asso-
ciated with susceptibility of reinfection with HPV and
HLA-DRB1*14 seems to confer protection against CC.
Results and discussion
This study is part of an open population project to
investigate asymptomatic women with HPV infection in
2002 (ML Garza-Rodríguez and HA Barrera-Saldaña,
unpublished results). One of the main objectives of this
work was to do a follow up of these women to deter-
mine the possible role of HLA class II genes in the fate
of the viral infection. Although it is known that class I
genes are very important in the immune response
because of their involvement in antigen presentation of
viral peptides on the surface of immune system cells, it
is also known that the presentation of these peptides by
class II alleles play a crucial role in protection by CD4+
lymphocytes.
All patients included, were HPV positive at the begin-
ning of the investigation in 2002. The group (n = 172)
was divided into three subgroups during their follow-up
in 2005 as follows: 1) HPV-persistent (n = 21), com-
posed of women who had a persistent viral infection,
meaning infection with the same HPV-type as in 2002
during their second visit (2005); 2) HPV-cleared group
(n =138), formed by women who eliminated the viral
infection by their second visit, evidenced by negative
molecular detection; and 3) HPV-reinfected (n = 13),
that consisted of women who eliminated the infection
but subsequently acquired a new infection with a dif-
ferent HPV-type, evidenced by molecular detection in
the cervical sample in 2005. No patient had developed
CC by the second visit of the study.
The mean age of the 172 women included in the ana-
lyses was 40.3 years (SD ± 11.2 years). All were residents
of the city of Monterrey, capital of the state of Nuevo
Leon, but only 55.9% were born in the state. The
remaining 44.1% averaged 30.4 years (SD ± 11.9 years)
(40.2%) living there with most being natives from the
neighboring state of San Luis Potosí (Table 1). At the
second visit, 34 women (19.7%) were positive for HPV
infection of which eight (23.5%) harbored co-infection
with multiple HPV types. The analysis showed that
61.5% of infections were caused by high-risk HPV types
(HR-HPV), 30.8% by low-risk types (LR-HPV) and 7.7%
Table 1 Characteristics of the study population and most
prevalent HPV types
N %
Study group 172 100
Age
Monterrey as city of residence 172 100
Monterrey, N.L. as birth city 96 55.9
City of birth different from Monterrey 76 44.1
HPV positive at 2002 172 100
HPV positive for any type at 2005 34 19.7
HPV Co-infections 8 23.5
HR-HPV 61.5
LR-HPV 30.8
Unknown oncogenic risk type viruses 7.7
HPV positive at 2005 but with the same
type as in 2002*
21 12.2
HPV-cleared at 2002 138 80.2
Most prevalent HPV types Type %
−83 38.1
−62 23.8
−18 19
−39, 52, 61, 84 14.3 (each)
−16, 51, 53, 81 9.5 (each)
*Persistent infection.
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most prevalent viral types were: HPV-83 (38.1%), HPV-62
(23.8%) and HPV-18 (19%), followed by HPV-39, -52, -61
and −84 (14.3% each) and for HPV-16, -51, 53 and 81
(9.5% each). Only 21 patients (12.2%) remained infected
with the same viral type (persistent infection), compared
with the results of the first visit in 2002 (Table 1).
Patients in the viral persistence group were consi-
dered cases to be contrasted against the other two
groups (HPV-cleared and HPV-reinfected), as well as
against a group of healthy Mexican women with a nor-
mal Papanicolaou smear (considered healthy individual
controls, n = 88) described elsewhere [27], and against a
group of Mexican women with CC (considered disease
controls, n = 104) described elsewhere as well [26] (both
were considered external controls). Since viral persis-
tence has been directly associated with the development
of premalignant lesions and CC, in order to search for
possible associations of alleles with susceptibility or
resistance to viral persistence and CC, we decided to
compare our three study groups with the previously
mentioned external control groups [26,27].
HLA-DQB1 alleles
HLA class II gene DQB1 genotyping analysis was
conducted in all 172 at the high resolution level. Allalleles were in Hardy-Weinberg equilibrium. The most
prevalent alleles were DQB1*03:02 [gene frequency
(g.f.) = 0.235], DQB1*03:01 (g.f. 0.218), DQB1*04:02
(g.f. 0.154), DQB1*02:01 (g.f. 0.122) and DQB1*05:01
(g.f. 0.078) (Table 2). When comparing the g.f. of alleles
found in the HPV-reinfected group against those of the
HPV-cleared group, we found that DQB1*05:01 was
associated with susceptibility to reinfection (p = 0.01,
OR = 4.9, CI 95% = 1.3 -18.7) (data not shown). No other
significant associations were observed; it was not pos-
sible to confirm the protective effect against progression
of the disease observed in Brazilians [8].
HLA-DRB1 alleles
For the analysis of the HLA-DRB1 locus, 95 patients
were included. We also divided these patients into the
three categories described above: 1) HPV-persistent
group, n = 21; 2) HPV-cleared, n = 61; and 3) HPV-
reinfected, n = 13. We calculated the number of subjects
required in the comparison group (HPV-cleared group)
to corroborate the presence of a significant difference;
this calculation indicated that a 1:3 ratio would be suffi-
cient for most comparisons. Base on this, and taking
into consideration the high cost to genotype HLA genes,
we decided to study 61 subjects in the HPV-cleared
group. These subjects were randomly selected from the
original group (n = 138).
The five alleles more frequently found in the HPV-
persistent group were: HLA-DRB1*04 (g.f. = 0.262),
DRB1*14 (g.f. = 0.143), DRB1*08 (g.f. = 0.119), DRB1*01
(g.f. = 0.095) and DRB1*11 (g.f. = 0.095). For the HPV-
cleared patients the most frequent alleles were HLA-
DRB1*04, DRB1*08, DRB1*07, DRB1*14 and DRB1*11,
with a g.f. of 0.262, 0.180, 0.107, 0.082 and 0.074,
respectively. The most common alleles found in the
HPV-reinfected group was HLA-DRB1*08, followed by
DRB1*07, DRB1*14, DRB1*01 and DRB1*03. All the g.f.
described above and those of the remaining studied
alleles found in the three groups and in the external
control groups, are shown in Table 3.
The results for the healthy individual external control
group [27], and those for the external disease control
group [26], respectively, are described in the first and
last columns of Table 3. The most frequent alleles of
the former group were HLA-DRB1*04, DRB1*08 and
DRB1*14 with the first two being also the most frequent
in the latter group.
DRB1*04 was found decreased in patients in the
HPV-reinfected group (Table 4) and this difference
was statistically significant when compared with the
patients in the HPV-persistent group (p = 0.02, OR = 8.8,
CI 95% = 1.0-196; Table 4) but no significant difference
was found in comparisons made against the rest of the
groups (data not shown). However, the DRB1*04 allele
Table 2 DQB1 allele gene frequencies (g.f.) in the studied
groups
HPV-Persistent HPV-cleared HPV-reinfected Total
N* = 42 N* = 276 N* = 26 N = 344
DQB1 n g.f. n g.f. n g.f. n g.f.
03:02 9 0.214 70 0.254 2 0.077 81 0.235
03:01 11 0.262 59 0.214 5 0.192 75 0.218
04:02 6 0.143 44 0.159 3 0.115 53 0.154
02:01 3 0.071 34 0.123 5 0.192 42 0.122
05:01 6 0.143 15 0.054 6 0.231 27 0.078
06:09 1 0.024 2 0.007 0 0.000 3 0.071
06:02 1 0.024 15 0.054 1 0.038 17 0.049
05:03 1 0.024 7 0.025 1 0.038 9 0.026
06:04 0 0.000 8 0.029 0 0.000 8 0.023
06:03 1 0.024 5 0.018 1 0.038 7 0.020
03:03 1 0.024 3 0.011 1 0.038 5 0.015
05:02 0 0.000 4 0.014 1 0.038 5 0.015
06:01 0 0.000 4 0.014 0 0.000 4 0.012
03:16 1 0.024 1 0.004 0 0.000 2 0.006
03:04 0 0.000 2 0.007 0 0.000 2 0.006
03:12 1 0.024 0 0.000 0 0.000 1 0.003
06:22 0 0.000 1 0.004 0 0.000 1 0.003
06:14 0 0.000 1 0.004 0 0.000 1 0.003
03:05 0 0.000 1 0.004 0 0.000 1 0.003
*N = number of alleles (n × 2).
Table 3 DRB1 allele gene frequencies (g.f.) in the studied gro
Healthy individuals26 HPV-Persistent HP
N* = 176 N* = 42 N*
DRB1 n g.f. n g.f. n
04 49 0.278 11 0.262 32
08 29 0.164 5 0.119 22
07 7 0.039 2 0.048 13
14 16 0.090 6 0.143 10
11 11 0.062 4 0.095 9
15 13 0.073 1 0.024 5
03 9 0.051 1 0.024 8
01 15 0.085 4 0.095 7
13 13 0.073 3 0.071 9
16 9 0.051 2 0.048 5
09 2 0.011 1 0.024 1
12 2 0.011 0 0.000 1
10 1 0.005 2 0.048 0
*N = number of alleles (n × 2).
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development in different Caucasian and Mexicans pa-
tients [27-29]. This finding suggests that the absence of
DRB1*04 is probably associated with an increased risk
of reinfection by different HPV genotypes. Although it
is difficult to draw this conclusion because the small
number of patients carrying the allele in the HPV-
reinfected group (only one, Table 3).
On the other hand, when comparing the HPV-cleared
group against the external healthy individuals group
[27] in order to explore the role of the HLA gene in
viral clearance, an increase in the g.f. of the DRB1*07
was observed in the former group (p = 0.04, OR = 2.88,
CI 95% = 1.03 – 8.3; Table 4). We also found the same
increase in the OR for that allele when pooling the three
groups (HPV-persistent + HPV-cleared +HPV-reinfected)
and comparing them against the external healthy indivi-
duals group (p = 0.04, OR = 2.7, CI 95% = 1.03-7.2; Table 4).
The three groups that were pooled for this analysis have
in common the fact that all patients were infected with
HPV and this was proved with the results of the 2002
genotyping results. Thus, the results suggest a probable
association between this allele and the risk of being
infected with HPV at some time in life. However, when we
analyzed the HPV-cleared group and the HPV-reinfected
group together (HPV-cleared +HPV-reinfected) and com-
pared them against a group formed by the HPV-persistent
group and cervical cancer external group (given that sub-
jects in the cervical cancer group must have had an HPV
persistent infection for cervical cancer development) a
protective role of this allele against viral persistence was
found (p = 0.03, OR = 0.42, IC 95% = 0.19-0.89; Table 4).ups
V-cleared HPV-reinfected Cervical cancer25
= 122 N* = 26 N* = 208
g.f. n g.f. n g.f.
0.262 1 0.038 63 0.3029
0.180 4 0.154 41 0.1971
0.107 4 0.154 11 0.0529
0.082 3 0.115 11 0.0529
0.074 2 0.077 8 0.0385
0.041 1 0.038 12 0.0577
0.066 3 0.115 13 0.0625
0.057 3 0.115 12 0.0577
0.074 1 0.038 16 0.0769
0.041 1 0.038 13 0.0625
0.008 0 0.000 0 0.0000
0.008 1 0.038 1 0.0048
0.000 2 0.077 7 0.0336
Table 4 Odds ratio of the HLA-DRB1 alleles found associated in the studied groups
Control group Case group Class II allele p value, OR and CI 95%
HPV-reinfected HPV-persistent DRB1*04 0.02, OR 8.8 (1.0 -196)
Healthy individuals HPV-cleared DRB1*07 0.04, OR 2.8 (1.03 -8.3)
Healthy individuals HPV-persistent + reinfected + cleared DRB1*07 0.04, OR 2.7 (1.03 -7.2)
HPV-cleared HPV-persistent + cervical cancer DRB1*07 0.05, OR 0.45 (0.20-1.02) n.s.
HPV-cleared + HPV-reinfected HPV-persistent + cervical cancer DRB1*07 0.03, OR 0.42 (0.19-0.89)
Healthy individuals HPV-persistent + cervical cancer DRB1*07 0.01, OR 0.31 (0.12-0.79)
Healthy individuals HPV-persistent + reinfected DRB1*10 0.03, OR 10.9 (1.12 -261)
Healthy individuals HPV-reinfected DRB1*10 0.04, OR 14.5 (1.27-167)
Healthy individuals HPV-persistent + cervical cancer DRB1*10 0.05, OR 6.53 (0.82-52) n.s.
Cervical cancer HPV-persistent DRB1*14 0.07, OR 0.34 (0.11 -1.09) n.s.
n.s. No significant.
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role of this allele against viral persistence but the asso-
ciation with risk of being infected in some point of the life.
To verify the protector role of this allele against a per-
sistent infection, an analysis comparing the healthy
individuals group against viral persistence group (HPV-
persistent + Cervical cancer groups) was conducted. With
this analysis it was possible to confirm (p = 0.01,
OR = 0.31, IC 95% = 0.12-0.79) the results about the pro-
tective role of DRB1*07 allele. This suggests that the
DRB1*07 allele may protect against viral persistence and
consequently, individuals carrying this allele, efficiently
eliminate HPV infection. It is important to mention and
take into account that the present study is an exploratory
work which should be confirmed in a larger number of
samples.
Comparing the g.f. of alleles found by grouping the
HPV-persistent and the HPV-reinfected groups and
comparing them against the external healthy individuals
group [27] an elevated OR value for the DRB1*10 allele
(p = 0.03, OR 10.9, CI 95% = 1.12 to 261,) was detected
(Table 4). The elevated value of the OR for the DRB1*10
allele (Table 4), showed a possible association between
this allele and the risk of being infected with HPV at
some point in life. There are no reports on the asso-
ciation of this allele with CC or HPV infection. The only
reports found in the literature are about its association
with diseases such as tuberculosis and rheumatoid
arthritis in others populations [30,31]. No association
was found when the three groups were pooled (HPV-
persistent + reinfected + cleared) and compared against
the healthy individuals group (data not shown). It was
not possible to make comparisons using the HPV-
cleared group alone, because there was not any patient
with DRB1*10 allele expression in that group. The only
association found for this allele was when the HPV-
reinfected group was compared against the healthy indi-
viduals group (p = 0.04, OR = 14.5, IC 95% = 1.27-167).Nonetheless, the clinical relevance of this finding about
the possible role of this allele in protection against an
HPV infection needs to be explore with a higher num-
ber of patients since the gene frequency of this allele
was low in the study population and no patient in the
HPV-cleared group was carrying the DRB1*10 allele
(Table 3).
Interestingly, the DRB1*14 allele showed a decreased
OR value of 0.34 (CI 95% = 0.11 to 1.09), when the latter
two groups were compared (Table 4). HLA-DRB1*14
allele is possibly associated with protection for deve-
loping CC in patients with viral persistence. This is the
first report of the protective role of this allele against CC
in Mexican women. In a previous similar study from our
population [26], it was found that particularly the
DRB1*15 allele was associated with a risk for CC and
no allele was associated with protection. These same
authors did not find any significant result for the
DRB1*14 allele. However, their study design was diffe-
rent from that of the present work. Indeed, while the
present study focused on HPV infection and persis-
tence in a cohort followed for three years, in the
referred study, the authors focused on confirmed cases
of CC. Therefore, it agrees with our finding of an asso-
ciation between the DRB1*14 allele and a low risk of
developing CC in women with viral persistence. In an-
other relevant study, Brazilian women from Sao Paulo,
with persistent HPV-infection, showed an association
between HLA class II alleles and natural history of CC
[8]. Some of the immunogenic peptides presented by
class I alleles could be part of larger peptides that are
presented through class II alleles. This could be the
case for the DRB1*14 allele that when presenting
certain peptides may help in preventing persistent
infections from evolving to CC.
Although the number of patients in the groups was
too low to allow any statistical comparisons between the
different haplotypes and genotypes formed with the
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possible that other variants of the HLA-DR gene could
be contributing risk to viral persistence as haplotypes
and even as genotypes. This data could be strengthened
by the characterization of allelic subtypes (which until
2010, more than 90 molecular variants have been
described). Likewise, the genotype for the patient in the
HPV-reinfected group carrying the DRB1*04 allele
(Table 3) is DRB1*04/DRB1*08 (data not shown) and a
comparison was made with the HPV-persistent group, in
which no patient was positive for the genotype pre-
viously mentioned (data not shown), although five
patients have the DRB1*04 allele in this group (Table 3,
HPV-persistent group, n =11, g.f. = 0.262) (OR = 18, CI
95% = 0.5 to 3.6) (data not shown). The information
above suggest that these individuals probably clear the
viral infection in an efficiently manner. This similarly
could be the case for the genotypes of the DRB1*07 al-
lele, having found two patients carrying this allele in the
HPV-persistent group under the genotypes DRB1*07/
DRB1*14 and DRB1*07/DRB1*01 (data not shown). This
other finding is interesting because in the HPV-cleared
group, eleven alleles were DRB1*07 and none were part
of the mentioned genotypes. These data support the
notion that DRB1*07 positive individuals are good
fighters of viral infection.
The protective role of the DQB1*03:01 allele has been
described in other populations [18-20]. Our study did
not confirm this association. Nevertheless, it is known
that in Mexicans there is a strong linkage disequilibrium
between this allele and the HLA-DRB1*04 allele [32].
Interestingly, in our study the aforementioned allele was
associated with a lower probability of evolving to CC.
Therefore, we consider it important to conduct an
extensive analysis of both class II genes to discern what
precise role they play in the presentation of peptides by
DRB1*04.
We attempted to make a comparison of haplotypes
and genotypes among groups in order to check if DQB1
alleles in the haplotypes were different, but the number
of patients was too low.
Conclusions
Our study suggests that it is necessary to identify genetic
markers of HPV infection susceptibility for each popu-
lation, since the distribution differs in distinct ethnic
groups. It also supports the notion that women who do
not adequately present the viral antigens, may require
comprehensive vaccination, while those with certain
protective alleles might require a different preventive
approach. Such is the case of women positive for
DRB1*14 or DRB1*07. It is evident that to adopt effec-
tive preventive approaches, it is be extremely helpful to
take into account the immunogenetic profile of thepopulation at risk, which in turn will be important given
the variation in the magnitude of CC risk in each unique
ethnic group.
Methods
Patients
The patients included in this study were recruited from
a group of 600 HPV infected women. Detection was
done using a polymerase chain reaction (PCR) in a
prevalence study that included a total of 3,082 women
in 2002 (ML Garza-Rodríguez and HA Barrera-Saldaña,
unpublished results). In total, 188 patients were re-
cruited during 2005–2006. Sixteen were excluded be-
cause of insufficient sample or due to pregnancy; thus,
172 women were included. The sample was divided into
three groups: 1) HPV-persistent group: patients with
the same HPV-type as in 2002 (n = 21); 2) HPV-cleared
group: patients that cleared their HPV infection
(n = 138); 3) HPV-reinfected group: patients with subse-
quent infections by an HPV-type different than that of
2002 (n = 13). Participants were fully informed of the
aim of the research project through informative ses-
sions. This study was a case–control analysis and all
patients read and signed an informed consent. The
protocol was approved by the Research and Ethics
Committee of all participant Institutions and have been
performed in accordance with the ethical standards laid
down in the 1964 Declaration of Helsinki and its later
amendments.
Cervical sampling and HPV detection
Cervical scrapes for HPV testing were taken using a
cervical brush (Colpotre® Chico, CA) and collected in li-
quid cytology medium. HPV detection was performed
by PCR amplification performed with the PGMY 09/11
primers system, followed by viral type discrimination
using reverse line blot (Roche Molecular Diagnostics,
Inc., Alameda, CA). PCR was carried out according pre-
vious methods [33,34]. HPV typing was performed by
reverse hybridization of the PCR product to oligonucleo-
tide probes for 37 HPV genotypes attached to a nylon
strip using colorimetric identification. Interpretation was
done according to the manufacturer’s insert.
HLA-DQB1 genotyping
Polymorphic variants within the second exon of DQB1
were detected by a reverse Dot-blot technique with the
INNO-Lipa HLA typing kits (Innogenetics, Inc., Gent,
Belgium). The interpretation was done using software
provided by the manufacturer.
HLA-DRB1 genotyping
The HLA-DRB1 alleles were detected with a PCR-
Luminex typing method using the Lifecodes HLA-SSO
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Diagnostics, Inc., Stamford, CT). DNA was PCR amp-
lified with biotinylated primers and the PCR products
were denatured and hybridized to the complementary
oligonucleotide probes attached to the microspheres
designed for the Luminex Instrument. The Luminex
Instrument is able to quantify the relative amounts of
labeled PCR product hybridizing to each Luminex
microsphere and types the probes as having positive
or negative reactivity with the amplified DNA sample.
Genotype determination and data analysis were per-
formed automatically, using the software provided
with the kit.
Statistical analyses
The observed genotype frequencies in the controls were
tested for Hardy-Weinberg equilibrium. The HLA
frequencies of DRB1 and DQB1 alleles were compared
between the groups using the two-sided Fisher exact test
with 2 × 2 contingency tables or, where appropriate, by
the χ2 test with Mantel-Haenszel correction; the p values
of < 0.05 were considered significant. The Bonferroni
correction for multiple tests was not required. Haldane’s
odds ratios (OR) within the 95% confidence interval (CI)
were calculated.
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